ARTICLE | Clinical News
MediGene begins Phase III trial
January 4, 2001 8:00 AM UTC
MediGene (NMarkt:MDG) began a 260-patient Phase III trial in Germany and Russia of PolyphenonE polyphenols to treat genital warts caused by human papillomavirus. The double-blind, placebo-controlled s...